<DOC>
	<DOCNO>NCT02328898</DOCNO>
	<brief_summary>The study objective ass safety efficacy Permanent Polymer Zotarolimus-Eluting Stent Resolute Integrity™ Polymer Free Amphilimus-Eluting Stent Cre8™ compare all-comer patient population . 1 month dual antiplatelet duration apply stable angina pectoris patient . Myocardial infarction patient population treat 12 month dual antiplatelet therapy .</brief_summary>
	<brief_title>Randomized `` All-comer '' Evaluation Permanent Polymer Resolute Integrity Stent Versus Polymer Free Cre8 Stent</brief_title>
	<detailed_description>A Prospective , Single-Center , Open Label , Randomized Controlled , two-arm Study Evaluate Safety Efficacy Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™ ' Compared Polymer Free Amphilimus Eluting Stent 'Cre8 ' . Dual Antiplatelet Therapy duration 1 Month apply stable angina pectoris patient population . Myocardial infarction patient population treat 12 month dual antiplatelet therapy ( DAPT ) . One thousand five hundred thirty-two ( 1532 ) patient ( 1:1 randomization Cre8 stent : Resolute Integrity™ stent ) enrol study , clinical follow-up 12 month assess primary end point . After period 12 month , clinical registry implement Information collect 3-years post procedure .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>General 1 . Allcomer patient age 18 year old 2 . Patient informed nature trial agree provision provide either oral emergency procedure , follow write informed consent , write informed consent case elective procedure approve Medical Research Ethics Committee ( MREC ) respective investigational site 3 . Patient eligible , accord heart team decision applicable , PCI implantation drugeluting stent ( DES ) 4 . Patient clinical evidence ischemic heart disease , angina pectoris , myocardial infarction , silent ischemia Angiographic 1 . All denovo lesion restenotic lesion ( whether native coronary bypass graft ) , amenable treatment drug elute balloon 2 . All lesion type allow : calcified lesion ( lesion preparation scoring/cutting rotational atherectomy allow ) , thrombus , chronic total occlusion ( CTO ; randomize successful wire cross predilatation ) , bifurcation lesion , ostial lesion , bypass graft ( venous arterial ) lesion leave main . 3 . There limit lesion length ; overlap stent allow , number lesion diseased vessel . 4 . Target vessel size reference ( visual estimation ) 2.5 mm 4.5 mm . 1 . Inability provide inform consent 2 . Participation another study intracoronary stent reach primary endpoint 3 . Planned surgery within next 3 month 4 . Known intolerance P2Y12 receptor antagonist would prevent adherence DAPT , intolerance aspirin , clopidogrel , Ticagrelor , Prasugrel , heparin/bivalirudin , contrast agent ( adequately premedicated ) component DES 5 . Female childbearing potential , pregnant planning become pregnant 6 . Life expectancy le 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Polymer free stent</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>